Your browser doesn't support javascript.
loading
Persistent Corneal Epithelial Defects: A Review Article.
Vaidyanathan, Uma; Hopping, Grant C; Liu, Harry Y; Somani, Anisha N; Ronquillo, Yasmyne C; Hoopes, Phillip C; Moshirfar, Majid.
Afiliação
  • Vaidyanathan U; McGovern Medical School, Health Science Center, University of Texas, Houston, TX, USA.
  • Hopping GC; McGovern Medical School, Health Science Center, University of Texas, Houston, TX, USA.
  • Liu HY; McGovern Medical School, Health Science Center, University of Texas, Houston, TX, USA.
  • Somani AN; McGovern Medical School, Health Science Center, University of Texas, Houston, TX, USA.
  • Ronquillo YC; Hoopes Durrie Rivera Research Center, Hoopes Vision, Draper, UT, USA.
  • Hoopes PC; Hoopes Durrie Rivera Research Center, Hoopes Vision, Draper, UT, USA.
  • Moshirfar M; Hoopes Durrie Rivera Research Center, Hoopes Vision, Draper, UT, USA.
Article em En | MEDLINE | ID: mdl-31598519
ABSTRACT
Persistent corneal epithelial defects (PEDs or PCEDs) result from the failure of rapid re-epithelialization and closure within 10-14 days after a corneal injury, even with standard supportive treatment. Disruptions in the protective epithelial and stromal layers of the cornea can render the eye susceptible to infection, stromal ulceration, perforation, scarring, and significant vision loss. Although several therapies exist and an increasing number of novel approaches are emerging, treatment of PEDs can still be quite challenging. It is important to treat the underlying causative condition, which may include an infection, limbal stem cell deficiency, or diabetes, in order to facilitate wound healing. Standard treatments, such as bandage contact lenses (BCLs) and artificial tears (ATs), aim to provide barrier protection to the epithelial layer. Recently-developed medical treatments can target the re-epithelialization process by facilitating access to growth factors and anti-inflammatory agents, and novel surgical techniques can provide re-innervation to the cornea. PEDs should be treated within 7-10 days to avoid secondary complications. These interventions, along with a step-wise approach to management, can be useful in patients with PEDs that are refractory to standard medical treatment. In this review, we discuss the epidemiology, etiology, diagnosis, current and novel management, and prognosis of persistent epithelial defects.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Med Hypothesis Discov Innov Ophthalmol Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Med Hypothesis Discov Innov Ophthalmol Ano de publicação: 2019 Tipo de documento: Article